VDR Genes and Vitamin D Dosing: What the Evidence Supports

Your vitamin D dose should be judged by what it does to your blood level, not by a VDR result on a genetic panel. People can show different rises in serum 25-hydroxyvitamin D (25OHD) after taking the same supplement, and genetics may contribute. But the direct evidence on the four best-known vitamin D receptor variants—BsmI, ApaI, TaqI, and FokI—does not support a validated genotype-specific dosing rule.

The reason is unusually straightforward: two recent systematic reviews reached opposite conclusions. One concluded that VDR variants modify the 25OHD response to supplementation; the larger, more recent meta-analysis of 16 randomized controlled trials involving 2,994 participants found no statistically significant overall difference for any of those four variants. When the headline result changes with analytical choices, a consumer-facing dosing algorithm has not earned its confidence.

Why VDR seemed like a promising target

Vitamin D does not act alone. After the body processes vitamin D, its active form binds the vitamin D receptor (VDR), which helps regulate gene activity in many tissues. That biology makes VDR a plausible candidate for differences in response. BsmI and FokI, along with ApaI and TaqI, have therefore become familiar names in vitamin D genetics.

Plausible does not mean predictive. A variant can associate with disease susceptibility, a laboratory marker, or a treatment response in one population without telling a healthy person how many international units of vitamin D3 to take. Those are separate claims requiring separate evidence.

VDR research does show that the gene has broad biological relevance. For example, a case-control study of 231 people with Parkinson's disease and 161 healthy blood donors found associations between several VDR variants, Parkinson's disease risk, and some adverse events from dopaminergic treatment. The 2022 Redenšek et al. study did not test vitamin D3 dosing or 25OHD response, so it cannot provide a dosing rule. The same distinction applies to association studies involving tuberculosis, asthma, atopy, inflammatory bowel disease, and other conditions.

Two meta-analyses, opposite conclusions

Usategui-Martín et al.'s 2022 systematic review and meta-analysis examined BsmI, ApaI, TaqI, and FokI in vitamin D supplementation studies and concluded that VDR polymorphisms modify the serum 25OHD response. That conclusion keeps the question open; it should not be brushed aside.

Yet Ghiasvand et al.'s 2023 systematic review and meta-analysis, which pooled 16 randomized controlled trials with 2,994 participants, found no statistically significant overall association between any of the same four VDR polymorphisms and the response of serum 25OHD to vitamin D supplementation. Its overall conclusion was that supplementation response was independent of VDR genotype.

The available reports do not provide a genotype-by-genotype mean difference in 25OHD for either meta-analysis. That omission matters. A statistically detectable difference can still be too small to change a real dosing decision. Without an effect size in nmol/L or ng/mL, no one can responsibly translate a p-value into "take more" or "take less."

The studies also converge on a more cautious observation: apparent genotype-related differences appear in subgroups, not as a stable overall result. Ghiasvand et al. reported signals after stratifying studies by duration, body mass index, health status, and ethnicity. Those same factors can independently affect supplementation response. A short study in a higher-BMI group may differ from a longer study in another population for many reasons besides VDR sequence.

Subgroup analyses can identify worthwhile hypotheses, but they multiply opportunities to find a chance result. The published summary does not report correction for the multiple subgroup comparisons. Nor does it report the between-study heterogeneity statistics needed to judge whether differences among trials drove the pattern. These limits do not prove the subgroup results are false; they do mean the results cannot yet carry a dosing recommendation.

VDR is only one stop in the pathway

The VDR-only story has another problem: vitamin D metabolism begins well before the receptor. Vitamin D must be converted to 25OHD, transported in the circulation, and later activated. Variants in genes involved in these steps, including CYP2R1 and GC, could affect measured vitamin D status or the response to a supplement.

A 2023 prospective cohort study by Ammar et al. followed 245 healthy adults receiving vitamin D supplementation and found that polymorphisms across vitamin D metabolism-related genes contributed to variation in 25OHD outcomes. The study supports a multi-gene view rather than a VDR-only one. It does not, however, provide a validated formula showing how much each variant should change a vitamin D3 dose.

Krasniqi et al.'s 2021 systematic review reached a similar conceptual conclusion across genes that include CYP2R1, CYP27B1, GC, VDR, and RXRA. It reviewed associations with vitamin D status and muscle mass or function, while also cataloging environmental influences such as season, latitude, skin pigmentation, age, and BMI. Neither this review nor the healthy-adult cohort partitions the response variance: the evidence cannot say how much of a person's response comes from VDR versus upstream genes, baseline 25OHD, body size, dose, or sun exposure.

A VDR result may be biologically interesting. It is not a calibrated vitamin D dose calculator.

Clinical studies do not fill the gap

One disease-specific randomized trial deserves careful handling. Yaghooti et al.'s 2021 study examined whether FokI genotype affected metabolic outcomes of calcitriol treatment in people with non-alcoholic fatty liver disease. Calcitriol is the fully active hormone, not ordinary cholecalciferol (vitamin D3). The participants also had a liver condition relevant to the conversion of D3 to 25OHD. Its result may matter for that clinical setting, but it cannot be extended to healthy adults choosing a standard D3 supplement.

Likewise, evidence that vitamin D supplementation can help a population does not establish a genetic dosing strategy. A 2024 meta-analysis of clinical trials in type 2 diabetes reported statistically significant improvements in HbA1c, fasting blood sugar, LDL, HDL, and systolic blood pressure. For HbA1c, the standardized mean difference was -0.15 (95% confidence interval, -0.29 to -0.20; I² = 79.76%); for fasting blood sugar, it was -0.28 (95% confidence interval, -0.40 to -0.15; I² = 70.13%). These are population-level findings in people with type 2 diabetes, not evidence that VDR testing identifies who should take a particular dose. The high heterogeneity also warrants restraint when interpreting the average effects.

What to do with a VDR result

Start with a serum 25OHD measurement, then reassess after a consistent supplementation period chosen with a clinician when appropriate. That approach measures the outcome of the entire system: supplement use, starting status, body size, sun exposure, diet, absorption, metabolism, and genetics. It tells you whether your current plan changed the biomarker you intended to change.

• Use 25OHD testing to guide adjustments instead of assigning a dose from BsmI, FokI, ApaI, or TaqI alone.
• Consider broader vitamin D pathway genetics as investigative context if 25OHD remains unexpectedly low despite consistent, reasonable supplementation and clinical evaluation.
• Do not treat disease-association findings as evidence that a VDR variant causes poor vitamin D3 response.
• Be skeptical of products that convert a VDR genotype into a precise IU recommendation. No trial in this evidence base validates such a protocol against clinical outcomes.

The honest conclusion is narrower than the marketing copy usually attached to nutrigenetic panels. Genetics may help explain some differences in vitamin D biology, and VDR remains a reasonable research candidate. But the best available randomized evidence does not show a clinically actionable overall VDR effect on 25OHD response, while another meta-analysis reaches the opposite conclusion. Until that conflict resolves with better effect estimates and prospectively designed trials, measure the blood level and adjust to the measured response.